We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-3.83%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$928M
AUM Growth
-$21.2M
Cap. Flow
+$44.5M
Cap. Flow %
4.8%
Top 10 Hldgs %
34.27%
Holding
87
New
4
Increased
25
Reduced
17
Closed
2

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$9.79M
2
CRL icon
Charles River Laboratories
CRL
+$9.03M
3
ISRG icon
Intuitive Surgical
ISRG
+$7.34M
4
PRCT icon
Procept Biorobotics
PRCT
+$7.3M
5
MDT icon
Medtronic
MDT
+$6.95M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$9.98M
2
ZBH icon
Zimmer Biomet
ZBH
+$9.91M
3
ELV icon
Elevance Health
ELV
+$8.16M
4
UNH icon
UnitedHealth
UNH
+$6.89M
5
MOH icon
Molina Healthcare
MOH
+$6.54M

Sector Composition

Rank Sector Weight
1 Healthcare 99.51%
2 Industrials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLAY icon
76
Relay Therapeutics
RLAY
$4.41B
$1.6M 0.17%
190,000
– –
NTLA icon
77
Intellia Therapeutics
NTLA
$1.69B
$1.58M 0.17%
50,000
– –
INSP icon
78
Inspire Medical Systems
INSP
$1.72B
$1.39M 0.15%
7,000
-8,400
-55% -$2.12M
TGTX icon
79
TG Therapeutics
TGTX
$7.65B
$1.34M 0.14%
160,000
+105,000
+191% +$1.46M
INMB icon
80
INmune Bio
INMB
$57.5M
$1.22M 0.13%
178,284
– –
EPIX
81
DELISTED
ESSA Pharma
EPIX
$1.1M 0.12%
356,500
– –
ALLO icon
82
Allogene Therapeutics
ALLO
$756M
$951K 0.1%
300,000
– –
OM icon
83
Outset Medical
OM
$89.9M
$544K 0.06%
3,333
-18,709
-85% -$4.42M
MRSN
84
DELISTED
Mersana Therapeutics
MRSN
$508K 0.05%
16,000
– –
TMO icon
85
Thermo Fisher Scientific
TMO
$222B
$253K 0.03%
500
– –
MOH icon
86
Molina Healthcare
MOH
$10.3B
– –
-21,700
Closed -$6.54M
RIGL icon
87
Rigel Pharmaceuticals
RIGL
$775M
– –
-25,383
Closed -$327K
1 2 3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2023 Portfolio in Review

As of Q3 2023, Rhenman & Partners Asset Management held 87 positions worth $928M, down 2.2% from $949M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rhenman & Partners Asset Management deployed $44.5M of net new capital in Q3 2023, opening 4 new positions and adding to 25 existing holdings. Its largest new stake was Charles River Laboratories: 44,000 shares worth $8.62M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Cigna, an estimated $9.98M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2023 buy was Charles River Laboratories: 44,000 shares worth $8.62M.
  • Rhenman & Partners Asset Management added most to Eli Lilly in Q3 2023, an estimated $9.79M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2023 reduction was Cigna, cutting an estimated $9.98M.
  • Rhenman & Partners Asset Management fully exited Molina Healthcare in Q3 2023, selling an estimated $6.54M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 34% of its $928M portfolio in Q3 2023.
  • Rhenman & Partners Asset Management opened 4 new positions and closed 2 in Q3 2023.
  • Rhenman & Partners Asset Management's portfolio value fell 2.2% quarter-over-quarter to $928M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.